Faisal Zain stands at the forefront of healthcare’s financial evolution, bringing decades of experience in medical technology and strategic infrastructure to the table. As an expert who has witnessed the friction between cutting-edge diagnostic innovation and the rigid systems of traditional finance, Zain offers a unique perspective on why many promising medical breakthroughs fail to reach their full commercial potential. In this conversation, we explore the launch of the FemTick accreditation and the systemic biases revealed in the most recent industry data. Our discussion covers the profound economic impact of outdated risk models, the specific hurdles preventing women’s health companies from scaling, and how a new coalition of banking and insurance leaders is finally building the infrastructure necessary to support a market expected to reach half a trillion dollars in the coming years.
When we look at the data showing that every single surveyed company in the women’s health space has encountered financial barriers, what does that struggle actually look like for a founder on the ground?
It is a constant, exhausting uphill battle that forces brilliant innovators to spend more time defending their business model than refining their technology. The reality is that these barriers lead to more than 60% of companies reporting direct revenue loss, which is a staggering figure when you consider the life-changing nature of their products. I have seen founders hit a wall where they cannot even set up basic payment processing because their clinical terminology is misunderstood by a bank’s compliance software. This doesn’t just slow them down; it creates a cascade of legal and operational costs that can drain a startup’s reserves before they even clear the regulatory hurdles. It is a visceral frustration to have a viable medical solution ready for the public while being treated like a high-risk liability by the very institutions meant to fuel growth.
How is it possible that in our current technological landscape, sophisticated medical solutions are still being flagged as high-risk or inappropriate by automated financial systems?
The problem is rooted in a massive disconnect between modern clinical innovation and the archaic algorithms used by major financial platforms. These automated risk models often use crude keyword triggers where essential medical terms like “menstrual,” “vagina,” or “sexual health” are incorrectly lumped into categories like adult content or unregulated lifestyle products. This misclassification is a relic of an era that didn’t recognize women’s health as a rigorous scientific and commercial powerhouse. Because these systems lack the nuance to distinguish a therapeutic device from high-risk digital content, legitimate healthcare companies find themselves locked out of the digital economy. It is essentially a “bias tax” that penalizes companies for being transparent about the biological realities they are working to improve.
What specific criteria does the FemTick accreditation use to determine if a financial or commercial service provider is actually equipped to support this sector?
The accreditation process is a deep dive into the operational DNA of a service provider, requiring them to meet a structured assessment threshold developed by CensHERship. We look at everything from leadership accountability and internal culture to the specific language written into their risk and underwriting policies. It is not enough for a bank or an insurer to simply say they support women’s health; they must prove that their internal systems have been updated to recognize the specific regulatory and operational needs of these businesses. We examine how these organizations classify and review women’s health clients to ensure they aren’t being unfairly throttled by outdated software. This visibility is crucial because it allows founders to identify partners who actually understand the market rather than those who might accidentally disrupt their operations.
In terms of insurance and capital access, how are founding partners like HSBC and Tokio Marine Kiln changing the way they evaluate risk for these innovators?
These founding partners are taking a proactive stance by acknowledging that they have a professional responsibility to build solutions that reflect the real opportunities in healthcare. For instance, underwriters at Tokio Marine Kiln are working to create clearer and fairer pathways for companies to scale by moving away from generic risk assessments that fail to capture the value of specialized medical products. They are looking at the sector on its own terms, recognizing that the “risk” is often a product of institutional misunderstanding rather than the actual business model. By having heavyweights like HSBC Innovation Banking involved, we are seeing a shift where women’s health is finally being treated as a high-quality innovation ecosystem. This shift provides the stability that founders need to commercialize their products and scale across international borders with confidence.
With the market opportunity for women’s health projected to reach $600 billion by 2030, how does this new financial infrastructure bridge the gap between current barriers and that massive economic potential?
Bridging this gap requires a total overhaul of the commercial “plumbing” that supports the healthcare industry, from ecommerce platforms to executive search firms. By bringing together a diverse group of partners—including legal experts from Mills & Reeve and advisory specialists from Withum—we are building a comprehensive support system that covers every stage of a company’s lifecycle. This infrastructure ensures that when a company is ready to scale, they aren’t held back by a lack of specialized insurance or a banking partner that doesn’t understand their cash flow needs. The goal is to make the financial side of the business so seamless that it becomes invisible, allowing the $600 billion in projected value to be realized through actual medical progress. When the structural bias is removed, we will see an explosion of growth that finally matches the scale of the unmet clinical needs we’ve been tracking for years.
What is your forecast for the women’s health sector as we move closer to the end of the decade?
I anticipate a complete normalization of the sector where the term “women’s health” is no longer seen as a niche or high-risk category, but as a primary driver of global healthcare ROI. As more organizations achieve FemTick accreditation from 2026 to 2030, the friction in payment processing and insurance underwriting will largely disappear, allowing for a surge of successful exits and public offerings. We will see the $600 billion market valuation become a reality because the infrastructure will finally be robust enough to support “unicorn” level scaling without the current operational bottlenecks. Ultimately, the success of this initiative will be felt in the doctor’s office, where patients will have access to technologies that were once held back by nothing more than a bank’s outdated keyword filter. The next few years will be defined by the transition from overcoming bias to achieving unprecedented commercial and clinical scale.
